Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stok Raporu

Piyasa değeri: US$34.8b

Alnylam Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Alnylam Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 70.5% ve 22.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 70.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 86% olacağı tahmin edilmektedir.

Anahtar bilgiler

70.5%

Kazanç büyüme oranı

70.6%

EPS büyüme oranı

Biotechs kazanç büyümesi27.5%
Gelir büyüme oranı22.4%
Gelecekteki özkaynak getirisi86.0%
Analist kapsamı

Good

Son güncelleme04 Nov 2024

Gelecekteki son büyüme güncellemeleri

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Recent updates

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 27

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ALNY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20263,45034371078420
12/31/20252,605-2017522230
12/31/20242,223-260-30-12330
9/30/20242,095-3321657N/A
6/30/20242,344-73319372N/A
3/31/20242,003-332128189N/A
12/31/20231,828-44042104N/A
9/30/20231,724-510-672N/A
6/30/20231,237-1,064-541-473N/A
3/31/20231,143-1,065-605-537N/A
12/31/20221,037-1,131-613-541N/A
9/30/2022961-1,182-632-559N/A
6/30/2022884-981-660-578N/A
3/31/2022880-893-654-577N/A
12/31/2021844-853-718-642N/A
9/30/2021749-838-691-615N/A
6/30/2021688-887-653-591N/A
3/31/2021571-876-672-604N/A
12/31/2020493-858-685-615N/A
9/30/2020401-891-775-688N/A
6/30/2020345-846-871-760N/A
3/31/2020286-886-452-336N/A
12/31/2019220-886-419-278N/A
9/30/2019169-821-372-233N/A
6/30/2019101-858-352-204N/A
3/31/201986-802-745-595N/A
12/31/201875-761-690-563N/A
9/30/201892-692-625-515N/A
6/30/2018107-570N/A-460N/A
3/31/201893-525N/A-438N/A
12/31/201790-491N/A-383N/A
9/30/201769-462N/A-358N/A
6/30/201766-443N/A-335N/A
3/31/201759-414N/A-324N/A
12/31/201647-410N/A-308N/A
9/30/201637-388N/A-282N/A
6/30/201630-361N/A-261N/A
3/31/201630-342N/A-247N/A
12/31/201541-290N/A-189N/A
9/30/201558-221N/A-173N/A
6/30/201562-188N/A-159N/A
3/31/201561-160N/A-150N/A
12/31/201451-360N/A-166N/A
9/30/201437-371N/A-151N/A
6/30/201435-357N/A-132N/A
3/31/201437-331N/A-109N/A
12/31/201347-89N/A-69N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ALNY önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ALNY önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ALNY önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ALNY şirketinin gelirinin (yıllık 22.4% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ALNY şirketinin gelirinin (yıllık 22.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ALNY 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 86 %).


Büyüyen şirketleri keşfedin